The Orphan Drug Act is a 1983 U.S. law designed to encourage pharmaceutical companies to develop treatments for rare diseases, defined as conditions affecting fewer than 200,000 people in the United States. Before the law existed, most rare diseases had no approved treatments because drug companies couldn’t justify the cost of development for such small patient populations. The act created a package of financial incentives to close that gap.
The Problem the Act Was Built to Solve
Developing a new drug costs hundreds of millions of dollars and takes years of research, testing, and regulatory review. For a company to recoup that investment, the drug typically needs a large enough customer base to generate sufficient revenue. When a disease affects only a few thousand people, the math doesn’t work. The potential sales simply can’t cover the development costs, let alone turn a profit.
Before 1983, this left millions of Americans with rare diseases in a difficult position. Their conditions were real and often serious, but no company had a financial reason to pursue treatments. These neglected conditions earned the label “orphan diseases” because no one was willing to adopt them. Congress passed the Orphan Drug Act specifically to change that equation by making rare disease drug development financially viable.
How the Act Creates Incentives
The Orphan Drug Act works by reducing the cost and risk of developing treatments for rare conditions while increasing the potential reward. It does this through several mechanisms that work together.
Market Exclusivity
The most powerful incentive is seven years of market exclusivity after a drug is approved. During that window, the FDA will not approve another version of the same drug for the same rare condition. This protection goes beyond standard patents. It gives a company a guaranteed period where it faces no direct competition, making it far more likely to recover its investment.
Tax Credits for Clinical Testing
The act originally established a 50% tax credit for expenses incurred during clinical trials for orphan drugs. Congress made this tax credit permanent in 1997. Clinical trials are one of the most expensive phases of drug development, so cutting that cost in half significantly lowers the financial barrier to pursuing a rare disease treatment.
Waived FDA Fees
Filing a drug application with the FDA comes with substantial fees, including application fees, product fees, and establishment fees. For orphan-designated drugs, these fees are waived. Application fees alone can run into the millions of dollars, so this waiver removes a meaningful financial hurdle, particularly for smaller companies and academic researchers working on rare disease therapies.
Research Grants
The FDA runs an Orphan Products Grants Program that has been funding clinical trials since the act’s passage in 1983. These grants go directly to clinical investigators and support trials evaluating the safety and effectiveness of drugs, biologics, medical devices, and medical foods for rare conditions. The program fills a gap that private investment alone can’t always cover, especially for the rarest diseases where even the act’s other incentives might not be enough to attract corporate interest.
What Qualifies as a Rare Disease
The act defines a rare disease as any disease or condition affecting fewer than 200,000 people in the United States. That threshold covers a wide range of conditions, from certain cancers and genetic disorders to rare infectious diseases. There are roughly 7,000 known rare diseases, and collectively they affect an estimated 25 to 30 million Americans. Most of these diseases are serious, chronic, and life-threatening.
To receive orphan drug designation, a company submits a request to the FDA demonstrating that the drug is intended to treat a condition meeting that prevalence threshold. Designation can happen at any stage of development, even before clinical trials begin, which means companies can start benefiting from the incentives early in the process.
Impact on Drug Development
The act’s effect has been dramatic. In the decade before the Orphan Drug Act, fewer than 40 drugs for rare diseases reached the U.S. market. Since its passage, the FDA has granted thousands of orphan designations and approved hundreds of orphan drugs. Entire categories of rare disease, from certain lysosomal storage disorders to rare pediatric cancers, now have treatment options that simply didn’t exist before.
The law has also shaped how other countries approach rare disease policy. The European Union, Japan, Australia, and several other countries have adopted similar orphan drug frameworks modeled on the U.S. act, each creating their own mix of incentives to address the same underlying market failure.
Criticisms and Ongoing Debate
The act has drawn criticism on several fronts. Some drugs that received orphan designation went on to become blockbusters, generating billions in revenue for conditions that, while technically rare, turned out to have broader applications. Critics argue that the incentives sometimes reward companies that don’t need them, particularly when a drug approved for a rare indication later gets prescribed for more common conditions.
Drug pricing is another concern. The market exclusivity provision, while essential for incentivizing development, also means patients with rare diseases sometimes face extremely high drug prices with no generic alternatives available for seven years. For conditions with very small patient populations, annual treatment costs can reach six figures per patient.
The Inflation Reduction Act of 2022 added a new layer to this debate. That law gave Medicare the ability to negotiate prices on certain high-cost drugs but included an exclusion for drugs with only an orphan designation for a single rare disease. This created controversy over whether some companies might use orphan status strategically to shield drugs from price negotiation, even when the drug also treats more common conditions.
Despite these tensions, the core purpose of the Orphan Drug Act remains broadly supported: rare disease patients deserve access to treatments, and without targeted incentives, the market alone won’t deliver them.